<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns="http://www.w3.org/TR/REC-html40">


<!-- Mirrored from medicain.net/DUOC THU QUOC GIA/Disopyramid.htm by HTTrack Website Copier/3.x [XR&CO'2013], Tue, 25 Mar 2014 18:06:50 GMT -->
<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 11">
<meta name=Originator content="Microsoft Word 11">
<link rel=File-List href="filelist-188.xml.html" tppabs="http://www.vietstarse.com/duocthu/Documents/Disopyramid_files/filelist.xml">
<link rel=Edit-Time-Data href="javascript:if(confirm('http://www.vietstarse.com/duocthu/Documents/Disopyramid_files/editdata.mso  \n\nThis file was not retrieved by Teleport Pro, because the server reports that this file cannot be found.  \n\nDo you want to open it from the server?'))window.location='http://www.vietstarse.com/duocthu/Documents/Disopyramid_files/editdata.mso'" tppabs="http://www.vietstarse.com/duocthu/Documents/Disopyramid_files/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<title>DISOPYRAMID</title>
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>VIETSTAR</o:Author>
  <o:LastAuthor>Ghost</o:LastAuthor>
  <o:Revision>3</o:Revision>
  <o:TotalTime>8</o:TotalTime>
  <o:Created>2006-08-08T14:04:00Z</o:Created>
  <o:LastSaved>2006-08-08T14:22:00Z</o:LastSaved>
  <o:Pages>2</o:Pages>
  <o:Words>2642</o:Words>
  <o:Characters>15060</o:Characters>
  <o:Company>VS</o:Company>
  <o:Lines>125</o:Lines>
  <o:Paragraphs>35</o:Paragraphs>
  <o:CharactersWithSpaces>17667</o:CharactersWithSpaces>
  <o:Version>11.5606</o:Version>
 </o:DocumentProperties>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:DoNotHyphenateCaps/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas>false</w:ValidateAgainstSchemas>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotUnderlineInvalidXML/>
  <w:Compatibility>
   <w:SelectEntireFieldWithStartOrEnd/>
   <w:UseWord2002TableStyleRules/>
  </w:Compatibility>
  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
 </w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState="false" LatentStyleCount="156">
 </w:LatentStyles>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:1627421319 -2147483648 8 0 66047 0;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:536871559 0 0 0 415 0;}
@font-face
	{font-family:TahomaH;
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-alt:Arial;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";}
h1
	{mso-style-next:Normal;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:10.0pt;
	font-family:Tahoma;
	mso-font-kerning:0pt;}
h2
	{mso-style-next:Normal;
	margin-top:4.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:2;
	font-size:9.0pt;
	font-family:Tahoma;}
h3
	{mso-style-next:Normal;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	mso-line-height-alt:10.5pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:3;
	layout-grid-mode:char;
	font-size:14.0pt;
	font-family:Tahoma;
	font-weight:normal;
	font-style:italic;}
h4
	{mso-style-next:Normal;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:4;
	font-size:9.0pt;
	font-family:Tahoma;
	font-weight:normal;}
h5
	{mso-style-next:Normal;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:5;
	font-size:9.0pt;
	font-family:Tahoma;}
h6
	{mso-style-next:Normal;
	margin-top:4.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.3pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:6;
	font-size:9.0pt;
	font-family:Tahoma;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-next:Normal;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:7;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";
	font-style:italic;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-next:Normal;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:8;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-next:Normal;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:9;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-noshow:yes;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	tab-stops:right 411.1pt;
	border:none;
	mso-border-bottom-alt:solid windowtext .5pt;
	padding:0in;
	mso-padding-alt:0in 0in 1.0pt 0in;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	tab-stops:center 3.0in right 6.0in;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{mso-style-noshow:yes;
	mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
span.MsoFootnoteReference
	{mso-style-noshow:yes;
	vertical-align:super;}
span.MsoCommentReference
	{mso-style-noshow:yes;
	mso-ansi-font-size:8.0pt;
	mso-bidi-font-size:8.0pt;}
span.MsoPageNumber
	{mso-ansi-font-size:9.0pt;
	mso-bidi-font-size:9.0pt;
	font-family:Tahoma;
	mso-ascii-font-family:Tahoma;
	mso-hansi-font-family:Tahoma;
	mso-bidi-font-family:Tahoma;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:TahomaH;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:TahomaH;
	font-weight:bold;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-2.0in;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:14.2pt;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";
	font-style:italic;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-14.15pt;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	mso-layout-grid-align:none;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-noshow:yes;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	background:navy;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";}
p.1, li.1, div.1
	{mso-style-name:1;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:center;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.1nho, li.1nho, div.1nho
	{mso-style-name:1nho;
	margin-top:3.5pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.2, li.2, div.2
	{mso-style-name:2;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	font-size:8.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";}
p.3, li.3, div.3
	{mso-style-name:3;
	mso-style-parent:2;
	margin-top:4.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.5, li.5, div.5
	{mso-style-name:5;
	mso-style-parent:2;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	font-size:8.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";
	font-style:italic;}
p.bai, li.bai, div.bai
	{mso-style-name:bai;
	mso-style-parent:"Heading 2";
	margin-top:25.0pt;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	text-align:center;
	line-height:10.4pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:2;
	font-size:10.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.BodyText21, li.BodyText21, div.BodyText21
	{mso-style-name:"Body Text 21";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	mso-line-height-alt:10.5pt;
	mso-pagination:widow-orphan;
	font-size:14.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";}
p.cach0, li.cach0, div.cach0
	{mso-style-name:"cach0\,4";
	margin-top:4.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.chucach, li.chucach, div.chucach
	{mso-style-name:chucach;
	margin-top:4.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.normal1, li.normal1, div.normal1
	{mso-style-name:normal1;
	mso-style-parent:"cach0\,4";
	margin-top:4.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.Style1, li.Style1, div.Style1
	{mso-style-name:Style1;
	mso-style-parent:"Heading 2";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:48.2pt;
	text-align:justify;
	text-indent:-17.0pt;
	line-height:150%;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:2;
	tab-stops:list 49.2pt;
	font-size:14.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;
	text-decoration:underline;
	text-underline:single;}
@page Section1
	{size:8.5in 11.0in;
	margin:1.0in 1.25in 1.0in 1.25in;
	mso-header-margin:.5in;
	mso-footer-margin:.5in;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-parent:"";
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-para-margin:0in;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-ansi-language:#0400;
	mso-fareast-language:#0400;
	mso-bidi-language:#0400;}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext="edit" spidmax="1027"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext="edit">
  <o:idmap v:ext="edit" data="1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=EN-US style='tab-interval:.5in'>

<div class=Section1>

<h1 align=center style='text-align:center;line-height:150%'><span lang=DE
style='font-size:9.0pt;mso-bidi-font-size:15.0pt;line-height:150%;font-family:
Verdana;mso-ansi-language:DE'>DISOPYRAMID<o:p></o:p></span></h1>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
lang=DE style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana;
mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><b><span
lang=DE style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana;
mso-ansi-language:DE'>Tên chung qu&#7889;c t&#7871;:</span></b><span lang=DE
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana;
mso-ansi-language:DE'> Disopyramide.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><b><span
lang=DE style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana;
mso-ansi-language:DE'>Mã ATC: </span></b><span lang=DE style='mso-bidi-font-size:
14.0pt;line-height:150%;font-family:Verdana;mso-ansi-language:DE'>C01B A03.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><b><span
lang=DE style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana;
mso-ansi-language:DE'>Lo&#7841;i thu&#7889;c: </span></b><span lang=DE
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana;
mso-ansi-language:DE'>Thu&#7889;c ch&#7889;ng lo&#7841;n nh&#7883;p.<o:p></o:p></span></p>

<p class=cach0 align=left style='margin-top:0in;text-align:left;line-height:
150%'><span lang=DE style='mso-bidi-font-size:14.0pt;line-height:150%;
font-family:Verdana;mso-ansi-language:DE'>D&#7841;ng thu&#7889;c và hàm l&#432;&#7907;ng<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
lang=DE style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana;
mso-ansi-language:DE'>Thu&#7889;c nang: 100 mg, 150 mg disopyramid base (dùng
d&#432;&#7899;i d&#7841;ng disopyramid phosphat).<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
lang=DE style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana;
mso-ansi-language:DE'>Thu&#7889;c nang, gi&#7843;i phóng kéo dài: 100 mg, 150
mg disopyramid base (dùng d&#432;&#7899;i d&#7841;ng disopyramid phosphat).<o:p></o:p></span></p>

<p class=cach0 align=left style='margin-top:0in;text-align:left;line-height:
150%'><span lang=DE style='mso-bidi-font-size:14.0pt;line-height:150%;
font-family:Verdana;mso-ansi-language:DE'>D&#432;&#7907;c lý và c&#417; ch&#7871;
tác d&#7909;ng<o:p></o:p></span></p>

<p class=MsoBodyText2 align=left style='margin-left:0in;text-align:left;
text-indent:0in;line-height:150%'><span lang=DE style='mso-bidi-font-size:14.0pt;
line-height:150%;font-family:Verdana;mso-ansi-language:DE'>Disopyramid là thu&#7889;c
ch&#7889;ng lo&#7841;n nh&#7883;p nhóm IA, t&#432;&#417;ng t&#7921; quinidin và
procainamid, có tác d&#7909;ng &#7913;c ch&#7871; c&#417; tim, làm gi&#7843;m
tính d&#7877; b&#7883; kích thích, t&#7889;c &#273;&#7897; d&#7851;n truy&#7873;n
và tính co c&#7911;a c&#417; tim. Disopyramid, gi&#7889;ng nh&#432; quinidin và
procainamid, c&#361;ng có nh&#7919;ng tính ch&#7845;t kháng - cholinergic có th&#7875;
làm thay &#273;&#7893;i nh&#7919;ng tác d&#7909;ng tr&#7921;c ti&#7871;p trên
c&#417; tim.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
lang=DE style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana;
mso-ansi-language:DE'>Disopyramid &#273;&#432;&#7907;c coi là m&#7897;t thu&#7889;c
ch&#7889;ng lo&#7841;n nh&#7883;p nhóm I (&#7893;n &#273;&#7883;nh màng). Gi&#7889;ng
nh&#432; nh&#7919;ng thu&#7889;c ch&#7889;ng lo&#7841;n nh&#7883;p nhóm I khác,
disopyramid g&#7855;n k&#7871;t v&#7899;i nh&#7919;ng kênh natri nhanh &#7903;
tr&#7841;ng thái không ho&#7841;t &#273;&#7897;ng và nh&#432; v&#7853;y làm gi&#7843;m
t&#7889;c &#273;&#7897; kh&#7917; c&#7921;c tâm tr&#432;&#417;ng &#7903; nh&#7919;ng
t&#7871; bào có tính t&#7921; &#273;&#7897;ng t&#259;ng.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
lang=DE style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana;
mso-ansi-language:DE'>Gi&#7889;ng nh&#432; quinidin, procainamid và lidocain,
disopyramid xóa tính t&#7921; &#273;&#7897;ng trong h&#7879; His - Purkinje.
Disopyramid làm gi&#7843;m tính t&#7921; &#273;&#7897;ng c&#7911;a nh&#7919;ng
trung tâm &#273;i&#7873;u nh&#7883;p th&#7845;t và nh&#297; l&#7841;c v&#7883;,
rút ng&#7855;n ho&#7863;c không làm thay &#273;&#7893;i th&#7901;i gian ph&#7909;c
h&#7891;i c&#7911;a nút xoang và làm gi&#7843;m t&#7889;c &#273;&#7897; d&#7851;n
truy&#7873;n trong nh&#297; và th&#7845;t. V&#7899;i nh&#7919;ng li&#7873;u
th&#432;&#7901;ng dùng, thu&#7889;c ít tác d&#7909;ng trên t&#7889;c &#273;&#7897;
d&#7851;n truy&#7873;n qua nút nh&#297; - th&#7845;t ho&#7863;c h&#7879; th&#7889;ng
His - Purkinje, nh&#432;ng gi&#7843;m t&#7889;c &#273;&#7897; d&#7851;n truy&#7873;n
qua &#273;&#432;&#7901;ng ph&#7909;. Disopyramid th&#432;&#7901;ng kéo dài th&#7901;i
k&#7923; tr&#417; h&#7919;u hi&#7879;u c&#7911;a nh&#297; và th&#7845;t. Thu&#7889;c
th&#432;&#7901;ng có ít tác d&#7909;ng trên th&#7901;i k&#7923; tr&#417; h&#7919;u
hi&#7879;u c&#7911;a nút nh&#297; - th&#7845;t ho&#7863;c h&#7879; His -
Purkinje. Tuy v&#7853;y, không tiên &#273;oán &#273;&#432;&#7907;c tác d&#7909;ng
trên nút nh&#297; - th&#7845;t &#7903; nh&#7919;ng ng&#432;&#7901;i b&#7879;nh
có r&#7889;i lo&#7841;n d&#7851;n truy&#7873;n t&#7915; tr&#432;&#7899;c. V&#7899;i
nh&#7919;ng li&#7873;u th&#432;&#7901;ng dùng, disopyramid gây ít ho&#7863;c
không gây kéo dài kho&#7843;ng PR ho&#7863;c ph&#7913;c h&#7907;p QRS,
nh&#432;ng kho&#7843;ng Q - T ho&#7863;c kho&#7843;ng Q - T hi&#7879;u ch&#7881;nh
theo t&#7889;c &#273;&#7897; (Q - Tc) có th&#7875; b&#7883; kéo dài.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
lang=DE style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana;
mso-ansi-language:DE'>V&#7899;i li&#7873;u &#273;i&#7873;u tr&#7883;,
disopyramid ít tác d&#7909;ng trên t&#7847;n s&#7889; xoang lúc ngh&#7881;, và
có tác d&#7909;ng tr&#7921;c ti&#7871;p gi&#7843;m l&#7921;c co c&#417; tim. &#7902;
ng&#432;&#7901;i b&#7879;nh không có r&#7889;i lo&#7841;n ch&#7913;c n&#259;ng
c&#417; tim, cung l&#432;&#7907;ng tim th&#432;&#7901;ng gi&#7843;m 10 - 15%. V&#7899;i
nh&#7919;ng li&#7873;u u&#7889;ng th&#432;&#7901;ng dùng, disopyramid th&#432;&#7901;ng
không &#7843;nh h&#432;&#7903;ng &#273;&#7871;n huy&#7871;t áp. Hi&#7871;m khi
x&#7843;y ra h&#7841; huy&#7871;t áp; huy&#7871;t áp tâm thu gi&#7843;m nhi&#7873;u
h&#417;n huy&#7871;t áp tâm tr&#432;&#417;ng. Disopyramid d&#432;&#7901;ng
nh&#432; không có tác d&#7909;ng alpha - ho&#7863;c beta - adrenergic. Thu&#7889;c
có tác d&#7909;ng kháng - cholinergic trên h&#7879; tiêu hóa và h&#7879; ni&#7879;u
- sinh d&#7909;c.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><i><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>In vitro</span></i><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>, ho&#7841;t
tính kháng - cholinergic c&#7911;a disopyramid kho&#7843;ng 0,06% so v&#7899;i
atropin.<o:p></o:p></span></p>

<h2 align=left style='margin-top:0in;text-align:left;line-height:150%'><i><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana;
font-weight:normal'>D&#432;&#7907;c &#273;&#7897;ng h&#7885;c<o:p></o:p></span></i></h2>

<p class=MsoBodyText2 align=left style='margin-left:0in;text-align:left;
text-indent:0in;line-height:150%'><span style='mso-bidi-font-size:14.0pt;
line-height:150%;font-family:Verdana'>Disopyramid phosphat &#273;&#432;&#7907;c
h&#7845;p thu nhanh qua &#273;&#432;&#7901;ng tiêu hóa, và 60 - 83% c&#7911;a
li&#7873;u vào &#273;&#7841;i tu&#7847;n hoàn d&#432;&#7899;i d&#7841;ng không
&#273;&#7893;i.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>N&#7891;ng
&#273;&#7897; disopyramid trong huy&#7871;t t&#432;&#417;ng, c&#7847;n thi&#7871;t
&#273;&#7875; gây &#273;áp &#7913;ng &#273;i&#7873;u tr&#7883;, thay &#273;&#7893;i
theo typ lo&#7841;n nh&#7883;p tim, m&#7913;c &#273;&#7897; nghiêm tr&#7885;ng,
th&#7901;i gian kéo dài lo&#7841;n nh&#7883;p, và &#273;&#7897; nh&#7841;y c&#7843;m
c&#7911;a ng&#432;&#7901;i b&#7879;nh &#273;&#7889;i v&#7899;i thu&#7889;c. Sau
m&#7897;t li&#7873;u u&#7889;ng 200 - 300 mg, tác d&#7909;ng th&#432;&#7901;ng
b&#7855;t &#273;&#7847;u trong vòng t&#7915; 30 phút &#273;&#7871;n 3,5 gi&#7901;
và kéo dài 1,5 - 8,5 gi&#7901;.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Disopyramid
&#273;&#432;&#7907;c phân b&#7889; kh&#7855;p d&#7883;ch ngoài t&#7871; bào c&#7911;a
c&#417; th&#7875; nh&#432;ng không g&#7855;n r&#7897;ng rãi vào các mô. &#7903;
n&#7891;ng &#273;&#7897; có tác d&#7909;ng &#273;i&#7873;u tr&#7883; trong huy&#7871;t
t&#432;&#417;ng, disopyramid trong máu &#273;&#432;&#7907;c phân b&#7889; g&#7847;n
b&#7857;ng nhau gi&#7919;a huy&#7871;t t&#432;&#417;ng và h&#7891;ng c&#7847;u.
&#7902; ng&#432;&#7901;i b&#7879;nh suy th&#7853;n, th&#7875; tích phân b&#7889;
h&#417;i gi&#7843;m.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>T&#7927;
l&#7879; disopyramid g&#7855;n vào protein huy&#7871;t t&#432;&#417;ng thay
&#273;&#7893;i và gi&#7843;m khi n&#7891;ng &#273;&#7897; thu&#7889;c và các ch&#7845;t
chuy&#7875;n hóa t&#259;ng; &#7903; n&#7891;ng &#273;&#7897; có tác d&#7909;ng
&#273;i&#7873;u tr&#7883; trong huy&#7871;t t&#432;&#417;ng, disopyramid g&#7855;n
v&#7899;i protein kho&#7843;ng 50 - 65%.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>N&#7917;a
&#273;&#7901;i trong huy&#7871;t t&#432;&#417;ng c&#7911;a disopyramid thay
&#273;&#7893;i t&#7915; 4 - 10 gi&#7901;, và kéo dài &#7903; ng&#432;&#7901;i b&#7879;nh
suy gan ho&#7863;c th&#7853;n. &#7902; ng&#432;&#7901;i b&#7879;nh có &#273;&#7897;
thanh th&#7843;i creatinin d&#432;&#7899;i 40 ml/phút, n&#7917;a &#273;&#7901;i
trong huy&#7871;t t&#432;&#417;ng bi&#7871;n &#273;&#7893;i t&#7915; 8 - 18 gi&#7901;.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Disopyramid
chuy&#7875;n hóa trong gan. &#7902; ng&#432;&#7901;i kh&#7887;e m&#7841;nh, n&#7891;ng
&#273;&#7897; trong huy&#7871;t t&#432;&#417;ng c&#7911;a ch&#7845;t chuy&#7875;n
hóa N - monodealkyl hóa c&#7911;a disopyramid là kho&#7843;ng 10% n&#7891;ng
&#273;&#7897; disopyramid. Ch&#7845;t chuy&#7875;n hóa N - monodealkyl hóa có
ho&#7841;t tính ch&#7889;ng lo&#7841;n nh&#7883;p y&#7871;u h&#417;n,
nh&#432;ng có ho&#7841;t tính kháng - cholinergic m&#7841;nh h&#417;n
disopyramid. &#7902; ng&#432;&#7901;i kh&#7887;e m&#7841;nh, kho&#7843;ng 40 -
60% li&#7873;u disopyramid u&#7889;ng &#273;&#432;&#7907;c th&#7843;i tr&#7915;
trong n&#432;&#7899;c ti&#7875;u d&#432;&#7899;i d&#7841;ng không thay &#273;&#7893;i,
15 - 25% d&#432;&#7899;i d&#7841;ng ch&#7845;t chuy&#7875;n hóa N - monodealkyl
hóa, và kho&#7843;ng 10% là nh&#7919;ng ch&#7845;t chuy&#7875;n hóa không xác
&#273;&#7883;nh; kho&#7843;ng 10% &#273;&#432;&#7907;c bài ti&#7871;t trong
phân d&#432;&#7899;i d&#7841;ng thu&#7889;c không thay &#273;&#7893;i và các ch&#7845;t
chuy&#7875;n hóa. pH n&#432;&#7899;c ti&#7875;u có v&#7867; không &#7843;nh
h&#432;&#7903;ng &#273;&#7871;n m&#7913;c th&#7843;i tr&#7915; disopyramid qua
th&#7853;n. Thu&#7889;c &#273;&#432;&#7907;c lo&#7841;i tr&#7915; b&#7857;ng
ph&#432;&#417;ng pháp th&#7849;m tách máu.<o:p></o:p></span></p>

<p class=cach0 align=left style='margin-top:0in;text-align:left;line-height:
150%'><span style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Ch&#7881;
&#273;&#7883;nh<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Disopyramid
&#273;&#432;&#7907;c dùng &#273;&#7875; ch&#7863;n và d&#7921; phòng tái phát c&#7911;a
lo&#7841;n nh&#7883;p th&#7845;t (ví d&#7909;, nh&#7883;p nhanh th&#7845;t kéo
dài) &#273;e d&#7885;a s&#7921; s&#7889;ng. D&#7921; phòng và &#273;i&#7873;u
tr&#7883; nh&#7883;p tim nhanh trên th&#7845;t (rung, cu&#7891;ng &#273;&#7897;ng
nh&#297;, nh&#7845;t là có nh&#7883;p th&#7845;t ch&#7853;m). Vì thu&#7889;c có
kh&#7843; n&#259;ng gây<b><i> </i></b>lo&#7841;n nh&#7883;p tim và vì không có
b&#7857;ng ch&#7913;ng ch&#7913;ng t&#7887; thu&#7889;c ch&#7889;ng lo&#7841;n
nh&#7883;p nhóm I t&#259;ng &#273;&#432;&#7907;c th&#7901;i gian s&#7889;ng,
nên không nên dùng disopyramid cho lo&#7841;n nh&#7883;p tim ít nghiêm tr&#7885;ng.
Tránh dùng disopyramid &#273;&#7875; &#273;i&#7873;u tr&#7883; ng&#432;&#7901;i
b&#7879;nh có ngo&#7841;i tâm thu th&#7845;t vô tri&#7879;u ch&#7913;ng.<o:p></o:p></span></p>

<p class=cach0 align=left style='margin-top:0in;text-align:left;line-height:
150%'><span style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Ch&#7889;ng
ch&#7881; &#273;&#7883;nh<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Ch&#7889;ng
ch&#7881; &#273;&#7883;nh disopyramid khi có s&#7889;c do tim, &#273;ã b&#7883;
bl&#7889;c nh&#297; - th&#7845;t &#273;&#7897; hai ho&#7863;c ba (n&#7871;u
không &#273;&#7863;t thi&#7871;t b&#7883; t&#7841;o nh&#7883;p tim), kho&#7843;ng
Q - T kéo dài b&#7849;m sinh, suy tim sung huy&#7871;t m&#7845;t bù ho&#7863;c
có gi&#7843;m huy&#7871;t áp, khi &#273;ã bi&#7871;t có m&#7851;n c&#7843;m v&#7899;i
thu&#7889;c.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Ch&#7889;ng
ch&#7881; &#273;&#7883;nh dùng &#273;&#7891;ng th&#7901;i disopyramid và
sparfloxacin.<o:p></o:p></span></p>

<p class=cach0 align=left style='margin-top:0in;text-align:left;line-height:
150%'><span style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Th&#7853;n
tr&#7885;ng<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>C&#361;ng
nh&#432; nh&#7919;ng thu&#7889;c ch&#7889;ng lo&#7841;n nh&#7883;p khác &#273;&#7875;
&#273;i&#7873;u tr&#7883; lo&#7841;n nh&#7883;p &#273;e d&#7885;a s&#7921; s&#7889;ng,
ph&#7843;i b&#7855;t &#273;&#7847;u li&#7879;u pháp disopyramid &#7903; b&#7879;nh
vi&#7879;n.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Vì
disopyramid có kh&#7843; n&#259;ng gây lo&#7841;n nh&#7883;p và vì các thu&#7889;c
ch&#7889;ng lo&#7841;n nh&#7883;p không ch&#7913;ng t&#7887; làm t&#259;ng th&#7901;i
gian s&#7889;ng &#273;&#7889;i v&#7899;i nh&#7919;ng ng&#432;&#7901;i b&#7879;nh
có lo&#7841;n nh&#7883;p không &#273;e d&#7885;a tính m&#7841;ng, disopyramid,
c&#361;ng nh&#432; nh&#7919;ng thu&#7889;c ch&#7889;ng lo&#7841;n nh&#7883;p
khác, ch&#7881; dành cho ng&#432;&#7901;i b&#7879;nh có lo&#7841;n nh&#7883;p
th&#7845;t &#273;e d&#7885;a s&#7921; s&#7889;ng.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Vì
disopyramid có tác d&#7909;ng kháng - cholinergic, nên không &#273;&#432;&#7907;c
dùng cho ng&#432;&#7901;i b&#7879;nh &#273;ã b&#7883; bí ti&#7875;u ti&#7879;n,
tr&#7915; phi &#273;ã áp d&#7909;ng nh&#7919;ng bi&#7879;n pháp &#273;i&#7873;u
tr&#7883; bí ti&#7875;u ti&#7879;n. Ph&#7843;i dùng th&#7853;n tr&#7885;ng
disopyramid &#7903; nh&#7919;ng ng&#432;&#7901;i b&#7879;nh có ti&#7873;n s&#7917;
gia &#273;ình v&#7873; t&#259;ng nhãn áp góc &#273;óng, và không &#273;&#432;&#7907;c
dùng disopyramid cho ng&#432;&#7901;i b&#7879;nh có t&#259;ng nhãn áp góc
&#273;óng, tr&#7915; phi có dùng li&#7879;u pháp cholinergic (ví d&#7909;, thu&#7889;c
nh&#7887; m&#7855;t pilocarpin) &#273;&#7875; làm m&#7845;t nh&#7919;ng tác d&#7909;ng
kháng - cholinergic c&#7911;a thu&#7889;c &#273;&#7889;i v&#7899;i m&#7855;t.
Ph&#7843;i dùng disopyramid &#273;&#7863;c bi&#7879;t th&#7853;n tr&#7885;ng &#7903;
nh&#7919;ng ng&#432;&#7901;i b&#7879;nh có b&#7879;nh nh&#432;&#7907;c c&#417;
vì thu&#7889;c có th&#7875; làm s&#7899;m x&#7843;y ra c&#417;n nh&#432;&#7907;c
c&#417; &#7903; nh&#7919;ng ng&#432;&#7901;i b&#7879;nh này.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Ph&#7843;i
&#273;i&#7873;u tr&#7883; gi&#7843;m kali huy&#7871;t, n&#7871;u b&#7883;
tr&#432;&#7899;c khi dùng disopyramid vì thu&#7889;c có th&#7875; không hi&#7879;u
qu&#7843; &#7903; nh&#7919;ng ng&#432;&#7901;i b&#7879;nh gi&#7843;m kali huy&#7871;t.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Không
dùng disopyramid cho nh&#7919;ng ng&#432;&#7901;i b&#7879;nh có suy tim sung
huy&#7871;t kém bù ho&#7863;c không bù, tr&#7915; phi suy tim v&#7851;n t&#7891;n
t&#7841;i sau li&#7879;u pháp t&#7889;i &#432;u (g&#7891;m c&#7843; vi&#7879;c
&#273;i&#7873;u tr&#7883; b&#7857;ng digitalis), và khi do m&#7897;t lo&#7841;n
nh&#7883;p (&#273;áp &#7913;ng t&#7889;t v&#7899;i disopyramid) gây nên ho&#7863;c
làm tr&#7847;m tr&#7885;ng thêm; ph&#7843;i theo dõi c&#7849;n th&#7853;n
ng&#432;&#7901;i b&#7879;nh.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Ng&#432;&#7901;i
b&#7879;nh có kho&#7843;ng Q - T kéo dài do quinidin có th&#7875; có nguy
c&#417; &#273;&#7863;c bi&#7879;t phát tri&#7875;n Q - T kéo dài và lo&#7841;n
nh&#7883;p x&#7845;u &#273;i trong khi &#273;i&#7873;u tr&#7883; b&#7857;ng
disopyramid. Ng&#432;&#7901;i b&#7879;nh có cu&#7891;ng &#273;&#7897;ng ho&#7863;c
rung nh&#297; ph&#7843;i &#273;&#432;&#7907;c &#273;i&#7873;u tr&#7883; b&#7857;ng
digitalis tr&#432;&#7899;c khi dùng disopyramid &#273;&#7875; &#273;&#7843;m b&#7843;o
t&#259;ng d&#7851;n truy&#7873;n nh&#297; - th&#7845;t không d&#7851;n t&#7899;i
nh&#7883;p th&#7845;t nhanh. Ph&#7843;i dùng th&#7853;n tr&#7885;ng disopyramid
cho ng&#432;&#7901;i b&#7879;nh có h&#7897;i ch&#7913;ng suy nút xoang (g&#7891;m
h&#7897;i ch&#7913;ng nh&#7883;p ch&#7853;m - nh&#7883;p nhanh), h&#7897;i ch&#7913;ng
Wolff - Parkinson - White, ho&#7863;c bl&#7889;c bó nhánh, vì không tiên
&#273;oán &#273;&#432;&#7907;c tác d&#7909;ng c&#7911;a thu&#7889;c trong nh&#7919;ng
b&#7879;nh &#273;ó.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Khi dùng
disopyramid, c&#7847;n xem xét kh&#7843; n&#259;ng h&#7841; &#273;&#432;&#7901;ng
huy&#7871;t &#7903; ng&#432;&#7901;i có nh&#7919;ng b&#7879;nh nh&#432; suy tim
sung huy&#7871;t, suy dinh d&#432;&#7905;ng m&#7841;n tính, b&#7879;nh gan ho&#7863;c
th&#7853;n ho&#7863;c &#273;ang dùng nh&#7919;ng thu&#7889;c (ví d&#7909;, thu&#7889;c
ch&#7865;n beta - adrenergic, r&#432;&#7907;u) có th&#7875; làm t&#7893;n h&#7841;i
c&#417; ch&#7871; thông th&#432;&#7901;ng &#273;i&#7873;u hòa glucose khi không
&#259;n; &#7903; nh&#7919;ng ng&#432;&#7901;i b&#7879;nh này, ph&#7843;i theo
dõi c&#7849;n th&#7853;n glucose huy&#7871;t.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Ph&#7843;i
dùng disopyramid th&#7853;n tr&#7885;ng và gi&#7843;m li&#7873;u &#7903;
ng&#432;&#7901;i b&#7879;nh suy th&#7853;n ho&#7863;c gan. Ph&#7843;i theo dõi
c&#7849;n th&#7853;n &#273;i&#7879;n tâm &#273;&#7891; &#7903; nh&#7919;ng
ng&#432;&#7901;i b&#7879;nh này.<o:p></o:p></span></p>

<p class=normal1 align=left style='margin-top:0in;text-align:left;line-height:
150%'><span style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Th&#7901;i
k&#7923; mang thai<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Disopyramid
&#273;i qua nhau thai. Cho &#273;&#7871;n nay ch&#432;a có nghiên c&#7913;u
&#273;&#7847;y &#273;&#7911; và &#273;ã &#273;&#432;&#7907;c ki&#7875;m tra v&#7873;
vi&#7879;c dùng disopyramid phosphat &#7903; ng&#432;&#7901;i mang thai; kinh
nghi&#7879;m s&#7917; d&#7909;ng thu&#7889;c trong th&#7901;i k&#7923; mang
thai còn h&#7841;n ch&#7871;. Không th&#7875; lo&#7841;i tr&#7915; kh&#7843;
n&#259;ng thu&#7889;c gây &#273;&#7897;c h&#7841;i &#273;&#7889;i v&#7899;i
thai. Có báo cáo là disopyramid kích thích co bóp t&#7917; cung mang thai. Ch&#7881;
dùng disopyramid trong th&#7901;i k&#7923; mang thai khi nh&#7919;ng l&#7907;i
ích có th&#7875; &#273;&#7841;t &#273;&#432;&#7907;c bi&#7879;n minh cho nh&#7919;ng
nguy c&#417; có th&#7875; x&#7843;y ra &#273;&#7889;i v&#7899;i thai.<o:p></o:p></span></p>

<p class=normal1 align=left style='margin-top:0in;text-align:left;line-height:
150%'><span style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Th&#7901;i
k&#7923; cho con bú<o:p></o:p></span></p>

<p class=MsoBodyText2 align=left style='margin-left:0in;text-align:left;
text-indent:0in;line-height:150%'><span style='mso-bidi-font-size:14.0pt;
line-height:150%;font-family:Verdana'>Disopyramid &#273;&#432;&#7907;c phân b&#7889;
trong s&#7919;a. Vì có th&#7875; x&#7843;y ra nh&#7919;ng tác d&#7909;ng không
mong mu&#7889;n nghiêm tr&#7885;ng &#7903; tr&#7867; bú m&#7865;, c&#7847;n cân
nh&#7855;c xem nên ng&#7915;ng cho bú hay ng&#7915;ng dùng thu&#7889;c, tính
&#273;&#7871;n t&#7847;m quan tr&#7885;ng c&#7911;a thu&#7889;c &#273;&#7889;i
v&#7899;i ng&#432;&#7901;i m&#7865;.<o:p></o:p></span></p>

<p class=normal1 align=left style='margin-top:0in;text-align:left;line-height:
150%'><span style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Tác
d&#7909;ng không mong mu&#7889;n (ADR)<o:p></o:p></span></p>

<p class=MsoBodyText2 align=left style='margin-left:0in;text-align:left;
text-indent:0in;line-height:150%'><span style='mso-bidi-font-size:14.0pt;
line-height:150%;font-family:Verdana'>TDKMM n&#7863;ng nh&#7845;t là h&#7841;
huy&#7871;t áp và suy tim sung huy&#7871;t. TDKMM th&#432;&#7901;ng g&#7863;p
ph&#7909; thu&#7897;c vào li&#7873;u, và có liên quan v&#7899;i tính kháng -
cholinergic c&#7911;a thu&#7889;c. TDKMM này có th&#7875; nh&#7845;t th&#7901;i,
nh&#432;ng có th&#7875; lâu dài ho&#7863;c nghiêm tr&#7885;ng. Bí ti&#7875;u ti&#7879;n
là tác d&#7909;ng kháng - cholinergic nghiêm tr&#7885;ng nh&#7845;t.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><i><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Th&#432;&#7901;ng
g&#7863;p, ADR &gt; 1/100</span></i><span style='mso-bidi-font-size:14.0pt;
line-height:150%;font-family:Verdana'><o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Ni&#7879;u
- sinh d&#7909;c: Bí ti&#7875;u ti&#7879;n.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Tim m&#7841;ch:
Ðau ng&#7921;c, suy tim sung huy&#7871;t, h&#7841; huy&#7871;t áp.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>N&#7897;i
ti&#7871;t và chuy&#7875;n hóa: Gi&#7843;m kali huy&#7871;t.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Tiêu
hóa: Ðau d&#7841; dày, tr&#432;&#7899;ng b&#7909;ng, khô mi&#7879;ng.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Th&#7847;n
kinh - c&#417; và x&#432;&#417;ng: Y&#7871;u c&#417;.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>M&#7855;t:
Nhìn m&#7901;.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><i><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Ít g&#7863;p,
1/1000 &lt; ADR &lt; 1/100<o:p></o:p></span></i></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Tim m&#7841;ch:
Ng&#7845;t và r&#7889;i lo&#7841;n d&#7851;n truy&#7873;n, bao g&#7891;m bl&#7889;c
nh&#297; - th&#7845;t, giãn r&#7897;ng ph&#7913;c h&#7907;p QRS và kéo dài kho&#7843;ng<br>
Q - T.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>H&#7879;
th&#7847;n kinh trung &#432;&#417;ng: M&#7879;t m&#7887;i, khó ch&#7883;u, kích
&#273;&#7897;ng, lo&#7841;n tâm th&#7847;n c&#7845;p, tr&#7847;m c&#7843;m,
chóng m&#7863;t, nh&#7913;c &#273;&#7847;u, &#273;au &#273;&#7899;n.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Da: Ban
toàn thân.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>N&#7897;i
ti&#7871;t và chuy&#7875;n hóa: Gi&#7843;m &#273;&#432;&#7901;ng huy&#7871;t,
có th&#7875; gây co bóp t&#7917; cung mang thai, t&#259;ng kali huy&#7871;t có
th&#7875; làm t&#259;ng &#273;&#7897;c tính, t&#259;ng cholesterol và
triglycerid - huy&#7871;t.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Tiêu
hóa: Táo bón, bu&#7891;n nôn, nôn, &#7881;a ch&#7843;y, &#273;&#7847;y
h&#417;i, chán &#259;n, t&#259;ng cân, h&#7885;ng khô.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Gan: &#7912;
m&#7853;t &#7903; gan&#259;ntng các men gan.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>M&#7855;t:
M&#7855;t khô.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Hô h&#7845;p:
Khó th&#7903;, m&#361;i khô.<o:p></o:p></span></p>

<p class=cach0 align=left style='margin-top:0in;text-align:left;line-height:
150%'><span style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>H&#432;&#7899;ng
d&#7851;n cách x&#7917; trí ADR<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>N&#7871;u
h&#7841; huy&#7871;t áp x&#7843;y ra &#7903; ng&#432;&#7901;i b&#7879;nh
&#273;ang dùng disopyramid và không ph&#7843;i do lo&#7841;n nh&#7883;p gây
nên, ph&#7843;i ng&#7915;ng disopyramid, và n&#7871;u c&#7847;n, ch&#7881; b&#7855;t
&#273;&#7847;u l&#7841;i v&#7899;i li&#7873;u l&#432;&#7907;ng th&#7845;p
h&#417;n, sau khi &#273;ã gi&#7843;i quy&#7871;t suy tim.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>N&#7871;u
suy tim sung huy&#7871;t n&#7863;ng d&#7847;n x&#7843;y ra &#7903; ng&#432;&#7901;i
b&#7879;nh &#273;ang dùng disopyramid, ph&#7843;i ng&#7915;ng disopyramid, và n&#7871;u
c&#7847;n, ch&#7881; b&#7855;t &#273;&#7847;u l&#7841;i v&#7899;i li&#7873;u
l&#432;&#7907;ng th&#7845;p h&#417;n, sau khi &#273;ã gi&#7843;i quy&#7871;t
suy tim.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>N&#7871;u
bl&#7889;c nh&#297; - th&#7845;t &#273;&#7897; I phát tri&#7875;n &#7903;
ng&#432;&#7901;i b&#7879;nh &#273;ang dùng disopyramid, ph&#7843;i gi&#7843;m
li&#7873;u l&#432;&#7907;ng. N&#7871;u bl&#7889;c nh&#297; - th&#7845;t &#273;&#7897;
I v&#7851;n t&#7891;n t&#7841;i, ph&#7843;i cân nh&#7855;c gi&#7919;a l&#7907;i
ích c&#7911;a vi&#7879;c ch&#7889;ng lo&#7841;n nh&#7883;p b&#7857;ng
disopyramid và nguy c&#417; có th&#7875; x&#7843;y ra bl&#7889;c nh&#297; - th&#7845;t
&#7903; m&#7913;c &#273;&#7897; cao h&#417;n. N&#7871;u x&#7843;y ra bl&#7889;c
nh&#297; - th&#7845;t &#273;&#7897; II ho&#7863;c &#273;&#7897; III, ho&#7863;c
bl&#7889;c m&#7897;t bó, hai bó, ho&#7863;c ba bó, ph&#7843;i ng&#7915;ng thu&#7889;c,
tr&#7915; phi nh&#7883;p th&#7845;t &#273;&#432;&#7907;c ki&#7875;m soát &#273;&#7847;y
&#273;&#7911; b&#7857;ng máy t&#7841;o nh&#7883;p. Khi ph&#7913;c h&#7907;p QRS
giãn quá r&#7897;ng ho&#7863;c kho&#7843;ng Q - T kéo dài xu&#7845;t hi&#7879;n,
ph&#7843;i theo dõi ch&#7863;t ch&#7869; ng&#432;&#7901;i b&#7879;nh, và ph&#7843;i
ng&#7915;ng thu&#7889;c n&#7871;u ph&#7913;c h&#7907;p QRS giãn r&#7897;ng ho&#7863;c
kho&#7843;ng Q - T kéo dài t&#7899;i 25 - 50%.<o:p></o:p></span></p>

<p class=normal1 align=left style='margin-top:0in;text-align:left;line-height:
150%'><span style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Li&#7873;u
l&#432;&#7907;ng và cách dùng<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><i><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Cách dùng:</span></i><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'><o:p></o:p></span></p>

<p class=MsoBodyText2 align=left style='margin-left:0in;text-align:left;
text-indent:0in;line-height:150%'><span style='mso-bidi-font-size:14.0pt;
line-height:150%;font-family:Verdana'>Disopyramid phosphat dùng u&#7889;ng. C&#7847;n
theo dõi &#273;i&#7879;n tâm &#273;&#7891; trong khi &#273;i&#7873;u tr&#7883;
b&#7857;ng disopyramid, &#273;&#7863;c bi&#7879;t khi dùng thu&#7889;c cho
ng&#432;&#7901;i b&#7879;nh có nguy c&#417; cao v&#7873; TDKMM nh&#432;
ng&#432;&#7901;i có b&#7879;nh tim n&#7863;ng, t&#259;ng huy&#7871;t áp, ho&#7863;c
b&#7879;nh gan ho&#7863;c th&#7853;n.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><i><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Li&#7873;u
l&#432;&#7907;ng:<o:p></o:p></span></i></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Li&#7873;u
disopyramid phosphat &#273;&#432;&#7907;c bi&#7875;u th&#7883; theo disopyramid
base. Ph&#7843;i hi&#7879;u ch&#7881;nh li&#7873;u l&#432;&#7907;ng c&#7849;n
th&#7853;n tùy theo yêu c&#7847;u và &#273;áp &#7913;ng cá nhân, tr&#7841;ng
thái chung và tr&#7841;ng thái tim m&#7841;ch c&#7911;a ng&#432;&#7901;i b&#7879;nh.
Ph&#7843;i gi&#7843;m li&#7873;u &#7903; ng&#432;&#7901;i b&#7879;nh suy th&#7853;n
v&#7915;a ho&#7863;c n&#7863;ng, suy gan, có b&#7879;nh c&#417; tim, kh&#7843;
n&#259;ng không bù c&#7911;a tim, nh&#7891;i máu c&#417; tim c&#7845;p tính, và
cân n&#7863;ng d&#432;&#7899;i 50 kg.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>N&#7891;ng
&#273;&#7897; disopyramid trong huy&#7871;t t&#432;&#417;ng kho&#7843;ng 2 - 4
microgam/ml th&#432;&#7901;ng c&#7847;n thi&#7871;t &#273;&#7875; tr&#7883; lo&#7841;n
nh&#7883;p th&#7845;t; m&#7897;t s&#7889; ng&#432;&#7901;i b&#7879;nh c&#7847;n
dùng t&#7899;i 7 microgam/ml &#273;&#7875; tr&#7883; và d&#7921; phòng tái phát
nh&#7883;p th&#7845;t nhanh khó ch&#7919;a. Ð&#7897;c tính tim m&#7841;ch
th&#432;&#7901;ng liên quan &#273;&#7871;n n&#7891;ng &#273;&#7897; disopyramid
trong huy&#7871;t t&#432;&#417;ng l&#7899;n h&#417;n 9 microgam/ml.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Li&#7873;u
disopyramid th&#432;&#7901;ng dùng cho ng&#432;&#7901;i l&#7899;n là 400 - 800
mg m&#7895;i ngày, chia thành li&#7873;u nh&#7887;. Li&#7873;u disopyramid
th&#432;&#7901;ng dùng cho ng&#432;&#7901;i l&#7899;n cân n&#7863;ng h&#417;n
50 kg là 150 mg, c&#7913; 6 gi&#7901; m&#7897;t l&#7847;n, d&#432;&#7899;i d&#7841;ng
nang th&#432;&#7901;ng, ho&#7863;c 300 mg, c&#7913; 12 gi&#7901; m&#7897;t l&#7847;n,
d&#432;&#7899;i d&#7841;ng nang gi&#7843;i phóng kéo dài. Li&#7873;u
disopyramid th&#432;&#7901;ng dùng cho ng&#432;&#7901;i l&#7899;n cân n&#7863;ng
d&#432;&#7899;i 50 kg là 100 mg, c&#7913; 6 gi&#7901; m&#7897;t l&#7847;n,
d&#432;&#7899;i d&#7841;ng nang th&#432;&#7901;ng, ho&#7863;c 200 mg, c&#7913;
12 gi&#7901; m&#7897;t l&#7847;n, d&#432;&#7899;i d&#7841;ng nang gi&#7843;i
phóng kéo dài.<o:p></o:p></span></p>

<p class=MsoBodyText align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Khi c&#7847;n
ki&#7875;m soát nhanh lo&#7841;n nh&#7883;p th&#7845;t, có th&#7875; b&#7855;t
&#273;&#7847;u &#273;i&#7873;u tr&#7883; v&#7899;i 300 mg disopyramid (200 mg
&#273;&#7889;i v&#7899;i ng&#432;&#7901;i cân n&#7863;ng d&#432;&#7899;i 50 kg)
và sau &#273;ó là 150 mg, c&#7913; 6 gi&#7901; m&#7897;t l&#7847;n (d&#432;&#7899;i
d&#7841;ng nang th&#432;&#7901;ng); khi c&#7847;n ki&#7875;m soát nhanh lo&#7841;n
nh&#7883;p th&#7845;t không &#273;&#432;&#7907;c dùng nang gi&#7843;i phóng kéo
dài lúc b&#7855;t &#273;&#7847;u &#273;i&#7873;u tr&#7883;.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Th&#432;&#7901;ng
&#273;&#7841;t &#273;&#432;&#7907;c tác d&#7909;ng &#273;i&#7873;u tr&#7883; &#7903;
0,5 - 3 gi&#7901; sau khi dùng m&#7897;t li&#7873;u n&#7841;p ban &#273;&#7847;u
300 mg. N&#7871;u không có &#273;áp &#7913;ng &#273;i&#7873;u tr&#7883; và
không có tác d&#7909;ng &#273;&#7897;c x&#7843;y ra trong vòng 6 gi&#7901; sau
li&#7873;u ban &#273;&#7847;u 300 mg, có th&#7875; dùng li&#7873;u 200 mg v&#7899;i
nang th&#432;&#7901;ng c&#7913; 6 gi&#7901; m&#7897;t l&#7847;n. N&#7871;u
không có &#273;áp &#7913;ng v&#7899;i li&#7873;u này trong vòng 48 gi&#7901;,
ph&#7843;i ng&#7915;ng thu&#7889;c và áp d&#7909;ng li&#7879;u pháp khác ho&#7863;c
ph&#7843;i cho ng&#432;&#7901;i b&#7879;nh n&#7857;m vi&#7879;n, &#273;ánh giá
c&#7849;n th&#7853;n, và theo dõi liên t&#7909;c trong khi t&#259;ng li&#7873;u
disopyramid lên 250 mg ho&#7863;c 300 mg, c&#7913; 6 gi&#7901; m&#7897;t l&#7847;n.
&#7902; m&#7897;t s&#7889; ít ng&#432;&#7901;i b&#7879;nh có nh&#7883;p th&#7845;t
nhanh n&#7863;ng khó ch&#7919;a, c&#7847;n dùng t&#7899;i 400 mg, c&#7913; 6 gi&#7901;
m&#7897;t l&#7847;n. &#7902; ng&#432;&#7901;i b&#7879;nh có b&#7879;nh c&#417;
tim ho&#7863;c có th&#7875; tim m&#7845;t bù, không &#273;&#432;&#7907;c dùng
li&#7873;u n&#7841;p ban &#273;&#7847;u, li&#7873;u ban &#273;&#7847;u không
&#273;&#432;&#7907;c dùng quá 100 mg và c&#7913; 6 gi&#7901; m&#7897;t l&#7847;n.
Ph&#7843;i hi&#7879;u ch&#7881;nh li&#7873;u l&#432;&#7907;ng c&#7849;n th&#7853;n
trong khi theo dõi ch&#7863;t ch&#7869; ng&#432;&#7901;i b&#7879;nh v&#7873; h&#7841;
huy&#7871;t áp và/ho&#7863;c suy tim sung huy&#7871;t.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Khi
ng&#432;&#7901;i b&#7879;nh có ch&#7913;c n&#259;ng th&#7853;n bình th&#432;&#7901;ng
&#273;ang dùng quinidin sulfat ho&#7863;c procainamid &#273;&#7893;i sang dùng
disopyramid, ph&#7843;i cho li&#7873;u disopyramid th&#432;&#7901;ng dùng
(không có li&#7873;u n&#7841;p ban &#273;&#7847;u) sau 6 - 12 gi&#7901; li&#7873;u
quinidin sulfat cu&#7889;i cùng, ho&#7863;c 3 - 6 gi&#7901; sau li&#7873;u
procainamid cu&#7889;i cùng. N&#7871;u ng&#7915;ng quinidin ho&#7863;c
procainamid có th&#7875; gây lo&#7841;n nh&#7883;p &#273;e d&#7885;a s&#7921; s&#7889;ng,
ng&#432;&#7901;i b&#7879;nh ph&#7843;i n&#7857;m b&#7879;nh vi&#7879;n và
&#273;&#432;&#7907;c theo dõi ch&#7863;t ch&#7869;. Khi &#273;&#7893;i d&#7841;ng
thu&#7889;c t&#7915; nang th&#432;&#7901;ng disopyramid sang nang gi&#7843;i
phóng kéo dài, có th&#7875; b&#7855;t &#273;&#7847;u dùng nang gi&#7843;i phóng
kéo dài 6 gi&#7901; sau khi dùng nang th&#432;&#7901;ng cu&#7889;i cùng.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>&#7902;
tr&#7867; em, chia t&#7893;ng li&#7873;u dùng m&#7895;i ngày thành nh&#7919;ng
li&#7873;u nh&#7887; b&#7857;ng nhau, c&#7913; 6 gi&#7901; dùng m&#7897;t l&#7847;n
ho&#7863;c &#7903; nh&#7919;ng kho&#7843;ng cách th&#7901;i gian theo nhu c&#7847;u
cá nhân. B&#7879;nh nhi ph&#7843;i n&#7857;m b&#7879;nh vi&#7879;n trong th&#7901;i
gian &#273;&#7847;u &#273;i&#7873;u tr&#7883;, và ph&#7843;i b&#7855;t &#273;&#7847;u
dò li&#7873;u v&#7899;i m&#7913;c th&#7845;p nh&#7845;t trong ph&#7841;m vi li&#7873;u
l&#432;&#7907;ng khuyên dùng; ph&#7843;i theo dõi ch&#7863;t ch&#7869; n&#7891;ng
&#273;&#7897; thu&#7889;c trong huy&#7871;t t&#432;&#417;ng và &#273;áp &#7913;ng
&#273;i&#7873;u tr&#7883;. Li&#7873;u l&#432;&#7907;ng disopyramid g&#7907;i ý
dùng cho b&#7879;nh nhi là 10 - 30 mg/kg/ngày &#273;&#7889;i v&#7899;i tr&#7867;
em d&#432;&#7899;i 1 tu&#7893;i; 10 - 20 mg/kg/ngày &#273;&#7889;i v&#7899;i tr&#7867;
em 1 - 4 tu&#7893;i; 10 - 15 mg/kg/ngày &#273;&#7889;i v&#7899;i tr&#7867; em 4
- 12 tu&#7893;i; và 6 - 15 mg/kg/ngày &#273;&#7889;i v&#7899;i tr&#7867; em 12
- 18 tu&#7893;i.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><i><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Li&#7873;u
l&#432;&#7907;ng trong tr&#432;&#7901;ng h&#7907;p suy gi&#7843;m ch&#7913;c
n&#259;ng th&#7853;n và gan:<o:p></o:p></span></i></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>&#7902;
ng&#432;&#7901;i b&#7879;nh có suy gi&#7843;m trung bình ch&#7913;c n&#259;ng
th&#7853;n (&#273;&#7897; thanh th&#7843;i creatinin l&#7899;n h&#417;n 40
ml/phút) ho&#7863;c suy gan, li&#7873;u disopyramid th&#432;&#7901;ng dùng là
100 mg, c&#7913; 6 gi&#7901; m&#7897;t l&#7847;n, d&#432;&#7899;i d&#7841;ng
nang th&#432;&#7901;ng, ho&#7863;c 200 mg, c&#7913; 12 gi&#7901; m&#7897;t l&#7847;n,
d&#432;&#7899;i d&#7841;ng nang gi&#7843;i phóng ch&#7853;m. Ð&#7875; ki&#7875;m
soát nhanh nh&#7883;p nhanh th&#7845;t &#7903; nh&#7919;ng ng&#432;&#7901;i b&#7879;nh
này, có th&#7875; dùng li&#7873;u b&#7855;t &#273;&#7847;u 200 mg (d&#432;&#7899;i
d&#7841;ng nang th&#432;&#7901;ng).<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>&#7902;
ng&#432;&#7901;i b&#7879;nh có suy gi&#7843;m n&#7863;ng ch&#7913;c n&#259;ng
th&#7853;n (&#273;&#7897; thanh th&#7843;i creatinin b&#7857;ng ho&#7863;c
d&#432;&#7899;i 40 ml/phút), li&#7873;u th&#432;&#7901;ng dùng disopyramid
(d&#432;&#7899;i d&#7841;ng nang th&#432;&#7901;ng) là 100 mg (có ho&#7863;c
không có li&#7873;u ban &#273;&#7847;u 150 mg) dùng &#7903; nh&#7919;ng kho&#7843;ng
cách x&#7845;p x&#7881; d&#432;&#7899;i &#273;ây tùy theo &#273;&#7897; thanh
th&#7843;i creatinin c&#7911;a ng&#432;&#7901;i b&#7879;nh:<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:408pt;
 height:117pt'>
 <v:imagedata src="Disopyramid_files/image001.png" o:title="untitled"/>
</v:shape><![endif]--><![if !vml]><img width=544 height=156
src="image002-20.jpg" tppabs="http://www.vietstarse.com/duocthu/Documents/Disopyramid_files/image002.jpg" v:shapes="_x0000_i1025"><![endif]><o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Không
dùng nang gi&#7843;i phóng kéo dài cho ng&#432;&#7901;i b&#7879;nh có &#273;&#7897;
thanh th&#7843;i creatinin b&#7857;ng ho&#7863;c d&#432;&#7899;i 40 ml/phút.<o:p></o:p></span></p>

<p class=cach0 align=left style='margin-top:0in;text-align:left;line-height:
150%'><span style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>T&#432;&#417;ng
tác thu&#7889;c<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><i><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Thu&#7889;c
ch&#7889;ng lo&#7841;n nh&#7883;p</span></i><span style='mso-bidi-font-size:
14.0pt;line-height:150%;font-family:Verdana'>: Khi dùng &#273;&#7891;ng th&#7901;i
disopyramid v&#7899;i nh&#7919;ng thu&#7889;c ch&#7889;ng lo&#7841;n nh&#7883;p
khác nh&#432; quinidin, procainamid, lidocain, encainid, flecainid ho&#7863;c
propafenon, tác d&#7909;ng trên tim có th&#7875; c&#7897;ng h&#7907;p ho&#7863;c
&#273;&#7889;i kháng, và &#273;&#7897;c tính có th&#7875; c&#7897;ng h&#7907;p.
Vi&#7879;c s&#7917; d&#7909;ng &#273;&#7891;ng th&#7901;i disopyramid và nh&#7919;ng
thu&#7889;c ch&#7889;ng lo&#7841;n nh&#7883;p này ch&#7881; nên dành &#273;&#7875;
&#273;i&#7873;u tr&#7883; lo&#7841;n nh&#7883;p &#273;e d&#7885;a s&#7921; s&#7889;ng
không &#273;áp &#7913;ng v&#7899;i li&#7879;u pháp dùng m&#7897;t thu&#7889;c.
Vi&#7879;c s&#7917; d&#7909;ng &#273;&#7891;ng th&#7901;i quinidin và
disopyramid &#273;ã d&#7851;n &#273;&#7871;n t&#259;ng nh&#7865; n&#7891;ng
&#273;&#7897; disopyramid trong huy&#7871;t t&#432;&#417;ng và gi&#7843;m nh&#7865;
n&#7891;ng &#273;&#7897; quinidin trong huy&#7871;t t&#432;&#417;ng.
Disopyramid không làm t&#259;ng n&#7891;ng &#273;&#7897; digoxin trong huy&#7871;t
t&#432;&#417;ng.<i><o:p></o:p></i></span></p>

<p class=MsoBodyText2 align=left style='margin-left:0in;text-align:left;
text-indent:0in;line-height:150%'><span style='mso-bidi-font-size:14.0pt;
line-height:150%;font-family:Verdana'>Không nên dùng &#273;&#7891;ng th&#7901;i
disopyramid v&#7899;i verapamil tiêm t&#297;nh m&#7841;ch ho&#7863;c u&#7889;ng,
vì có th&#7875; có s&#7921; c&#7897;ng h&#7907;p tác d&#7909;ng và suy ch&#7913;c
n&#259;ng th&#7845;t trái. Ph&#7843;i ng&#7915;ng disopyramid 48 gi&#7901;
tr&#432;&#7899;c khi b&#7855;t &#273;&#7847;u dùng verapamil và không
&#273;&#432;&#7907;c dùng l&#7841;i disopyramid cho t&#7899;i 24 gi&#7901; sau
khi ng&#7915;ng verapamil.<o:p></o:p></span></p>

<p class=MsoBodyText2 align=left style='margin-left:0in;text-align:left;
text-indent:0in;line-height:150%'><i><span style='mso-bidi-font-size:14.0pt;
line-height:150%;font-family:Verdana'>Thu&#7889;c kháng - cholinergic: </span></i><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Tác d&#7909;ng
kháng - cholinergic c&#7911;a disopyramid có th&#7875; c&#7897;ng h&#7907;p v&#7899;i
nh&#7919;ng thu&#7889;c kháng - cholinergic.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><i><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Thu&#7889;c
&#7843;nh h&#432;&#7903;ng &#273;&#7871;n enzym microsom gan:</span></i><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'> Nh&#7919;ng
thu&#7889;c (ví d&#7909;, phenytoin) gây c&#7843;m &#7913;ng enzym microsom gan
có th&#7875; làm t&#259;ng nhanh chuy&#7875;n hóa disopyramid. Khi dùng &#273;&#7891;ng
th&#7901;i nh&#7919;ng thu&#7889;c gây c&#7843;m &#7913;ng enzym microsom v&#7899;i
disopyramid, ph&#7843;i theo dõi ch&#7863;t ch&#7869; n&#7891;ng &#273;&#7897;
disopyramid trong huy&#7871;t thanh &#273;&#7875; tránh n&#7891;ng &#273;&#7897;
d&#432;&#7899;i m&#7913;c có tác d&#7909;ng &#273;i&#7873;u tr&#7883;.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><i><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Erythromycin
và sparfloxacin:</span></i><span style='mso-bidi-font-size:14.0pt;line-height:
150%;font-family:Verdana'> Dùng erythromycin và sparfloxacin cho m&#7897;t s&#7889;
ng&#432;&#7901;i b&#7879;nh &#273;ang dùng disopyramid &#273;ã d&#7851;n &#273;&#7871;n
t&#259;ng n&#7891;ng &#273;&#7897; disopyramid trong huy&#7871;t thanh, kéo dài
kho&#7843;ng Q - T, và nh&#7883;p th&#7845;t nhanh &#273;a d&#7841;ng.<o:p></o:p></span></p>

<p class=normal1 align=left style='margin-top:0in;text-align:left;line-height:
150%'><span style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Ð&#7897;
&#7893;n &#273;&#7883;nh và b&#7843;o qu&#7843;n<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>B&#7843;o
qu&#7843;n nang disopyramid phosphat trong l&#7885; kín, &#7903; nhi&#7879;t
&#273;&#7897; 20 - 25<sup>o</sup>C.<o:p></o:p></span></p>

<p class=cach0 align=left style='margin-top:0in;text-align:left;line-height:
150%'><span style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Quá
li&#7873;u và x&#7917; trí<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><i><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Bi&#7875;u
hi&#7879;n</span></i><span style='mso-bidi-font-size:14.0pt;line-height:150%;
font-family:Verdana'>:<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Quá li&#7873;u
disopyramid gây nh&#7919;ng tác d&#7909;ng kháng - cholinergic, m&#7845;t ý th&#7913;c,
h&#7841; huy&#7871;t áp, ng&#7915;ng th&#7903;, nh&#7919;ng c&#417;n ng&#7841;t
th&#7903;, r&#7889;i lo&#7841;n d&#7851;n truy&#7873;n tim, lo&#7841;n nh&#7883;p,
ph&#7913;c h&#7907;p QRS và kho&#7843;ng Q - T giãn r&#7897;ng, nh&#7883;p tim
ch&#7853;m, suy tim sung huy&#7871;t, vô tâm thu, và c&#417;n &#273;&#7897;ng
kinh. Quá li&#7873;u disopyramid &#273;ã gây t&#7917; vong.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><i><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Ði&#7873;u
tr&#7883;:</span></i><span style='mso-bidi-font-size:14.0pt;line-height:150%;
font-family:Verdana'><o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Ph&#7843;i
&#273;i&#7873;u tr&#7883; nhanh và m&#7841;nh khi quá li&#7873;u disopyramid
ngay c&#7843; khi không có tri&#7879;u ch&#7913;ng. Không có thu&#7889;c gi&#7843;i
&#273;&#7897;c &#273;&#7863;c hi&#7879;u &#273;&#7889;i v&#7899;i ng&#7897;
&#273;&#7897;c disopyramid. Ði&#7873;u tr&#7883; quá li&#7873;u disopyramid g&#7891;m
gây nôn ho&#7863;c r&#7917;a d&#7841; dày, li&#7879;u pháp h&#7895; tr&#7907;,
và theo dõi &#273;i&#7879;n tâm &#273;&#7891;. N&#7871;u c&#7847;n, có th&#7875;
s&#7917; d&#7909;ng glycosid tr&#7907; tim, thu&#7889;c l&#7907;i ti&#7875;u,
thu&#7889;c t&#259;ng huy&#7871;t áp và thu&#7889;c tác d&#7909;ng gi&#7889;ng
th&#7847;n kinh giao c&#7843;m (ví d&#7909;, isoproterenol, dopamin), và có th&#7875;
dùng máy hô h&#7845;p h&#7895; tr&#7907;. N&#7871;u x&#7843;y ra bl&#7889;c nh&#297;
- th&#7845;t n&#7863;ng d&#7847;n, có th&#7875; &#273;&#7863;t máy t&#7841;o nh&#7883;p
trong tim. Th&#7849;m tách máu có th&#7875; có ích.<o:p></o:p></span></p>

<p class=cach0 align=left style='margin-top:0in;text-align:left;line-height:
150%'><span style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Thông
tin qui ch&#7871;<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Thu&#7889;c
&#273;&#7897;c b&#7843;ng B.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'><o:p>&nbsp;</o:p></span></p>

</div>

</body>


<!-- Mirrored from medicain.net/DUOC THU QUOC GIA/Disopyramid.htm by HTTrack Website Copier/3.x [XR&CO'2013], Tue, 25 Mar 2014 18:06:50 GMT -->
</html>
